Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306
Publication
, Conference
Friend, R; Xenakis, J; Serody, JS; Comeau, T; Gabriel, DA; Sarantopoulos, S; Coghill, J; Wood, WA; Sharf, A; Whitley, JS; Rao, K; Walko, CM ...
Published in: BLOOD
December 3, 2015
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Friend, R., Xenakis, J., Serody, J. S., Comeau, T., Gabriel, D. A., Sarantopoulos, S., … Armistead, P. M. (2015). Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Friend, Reed, James Xenakis, Jonathan S. Serody, Terrance Comeau, Don A. Gabriel, Stefanie Sarantopoulos, James Coghill, et al. “Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Friend R, Xenakis J, Serody JS, Comeau T, Gabriel DA, Sarantopoulos S, et al. Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306. In: BLOOD. AMER SOC HEMATOLOGY; 2015.
Friend, Reed, et al. “Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.
Friend R, Xenakis J, Serody JS, Comeau T, Gabriel DA, Sarantopoulos S, Coghill J, Wood WA, Sharf A, Whitley JS, Rao K, Walko CM, Ivanova A, Shea TC, Armistead PM. Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306. BLOOD. AMER SOC HEMATOLOGY; 2015.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology